Title:
STAR Ph1 CX-4945 Basal Cell Carcinoma View
Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)
Indication:
Skin Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Title:
STAR BV in pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View
Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View
Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR Ph1/2 BLU667 thy NSCLC Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 BLU667 thy NSCLC Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 BLU667 thy NSCLC Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Indication:
Thyroid Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
TTFlds cncmnt w/ PTX recurrent ovn cnr View
Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer
Indication:
Ovarian Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Anal Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Bladder Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Bone Mets
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Brain Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Uterine Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vaginal Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Renal Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Sarcoma
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Testicular Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Malignant Adenoma
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Penile Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gastric Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kaposi's Sarcoma
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kidney Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Liver Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Cervical Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph2 Erdafitinib FGFR Solid Tumors View
Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)
Indication:
Solid Tumors
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View
Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised Multicentre Double-blind Placebo-controlled Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Biomarker DNA Defect Men Prostate View
Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Title:
STAR: PH2 Tuca+ Tras HER2+ CC View
Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)
Indication:
Colon Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR: PH2 Tuca+ Tras HER2+ CC View
Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)
Indication:
Rectal Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Bladder Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II
Title:
STAR Ph2 Ak104 Cervical Cancer View
Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)
Indication:
Cervical Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR PH3 Nirap Abira HRR mCSPC View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Ph1 CX-4945 Basal Cell Carcinoma View
Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)
Indication:
Skin Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Title:
STAR BV in pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View
Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View
Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: II
Title:
STAR Ph1/2 BLU667 thy NSCLC Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: I/II